收稿日期: 2024-05-30
录用日期: 2024-06-19
网络出版日期: 2024-06-25
基金资助
南京鼓楼医院临床研究专项资金(2022-LCYJ-MS-04)
Current status and challenges in diagnosis and treatment of systemic lupus erythematosus in China
Received date: 2024-05-30
Accepted date: 2024-06-19
Online published: 2024-06-25
系统性红斑狼疮（systemic lupus erythematosus, SLE）是一种以多系统损害为特征的自身免疫性疾病。我国SLE患者基数大、病情重、缓解率低、复发率高、感染风险高。2023年，研究显示，全球有SLE患者约341万例，其中我国患者达70万~100万例，总数位居首位。我国SLE患者的平均发病年龄为30.7岁，女性与男性的发病比为12∶1；脏器受累更为多见，其中肾脏受累率为45.02%，血液系统受累率为37.2%，均显著高于欧洲SLE患者（肾脏受累率为27.9%，血液系统受累率为18.2%）。我国SLE患者疾病治疗的临床缓解率为2.47%，而国际报道的缓解率达22.9%。当前，我国SLE患者的短期生存率基本与国际一致（5年可达94%），但长期生存率仍不容乐观，呈断崖式下跌，25~30年生存率仅为30%。我国有84.13%的SLE患者使用糖皮质激素治疗，而国际上SLE患者的糖皮质激素使用率仅为42.6%，感染是我国SLE患者死亡的首位原因，而西方国家SLE患者死因则主要为心血管疾病和肿瘤。随着新分类标准的提出、达标治疗理念的引入、新型治疗方法的运用，将大大推动SLE诊疗的发展，有望进一步改善我国患者的预后。
张昕 , 赵盛楠 , 冯学兵 . 中国系统性红斑狼疮的诊治现状及挑战[J]. 诊断学理论与实践, 2024 , 23(03) : 257 -262 . DOI: 10.16150/j.1671-2870.2024.03.002
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple system involvements. The number of SLE patients in China is large, and patients suffer more severe condition, with low remission rate ，high recurrence rate ，and high risk of infection.The situation of diagnosis and treatment for SLE is still serious. Relevant research released in 2023 shows that there are about 3.41 million cases of SLE patients in the world,and the number of patients in China amounts to 700 000-1 000 000, ranking the first in the world. The average onset age of SLE patients in China is 30.7 years old, and the incidence ratio of women to men is 12∶1.Organ involvement is more common in China, with 45.02% of renal involvement and 37.2% of haematological involvement, which are significantly higher than those in European patients with SLE (27.9% of renal involvement and 18.2% of haematological involvement). The clinical remission rate of SLE patients in China is 2.47%，while the relief rate reported internationally is 22.9%. Currently, the short-term survival rate of SLE patients in China is basically in line with that in the world (5-year survival rate reach 94%), but the long-term survival rate is still not optimistic, declining sharply, with a 25-30 year survival rate of only 30%. In China, 84.13% of SLE patients receive glucocorticoid（GC）therapy, while 42.6% SLE patients receive GC in the world. Infection is the leading cause of death for SLE patients in China, while in western countries, the main causes of death for SLE patients are cardiovascular disease and tumors With the proposal of new classification standards, the introduction of the concept of up-to-date treatment, as well as the use of new treatment methods, the development of SLE diagnosis and treatment will be greatly promoted, and it is expected to further improve the prognosis of patients in China.
| [1] | TEKTONIDOU M G, DASGUPTA A, WARD M M. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis[J]. Arthritis Rheumatol, 2016, 68(6):1432-1441. |
| [2] | TEKTONIDOU M G, LEWANDOWSKI L B, HU J, et al. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016[J]. Ann Rheum Dis, 2017, 76(12):2009-2016. |
| [3] | 曾小峰, 李梦涛, 田新平. 中国系统性红斑狼疮发展报告2020[M]. 辽宁: 辽宁科学技术出版社, 2021. |
| ZENG X F, LI M T, TIAN X P. Systemic lupus erythematosus in China: A national report of 2020[M]. Liaoning: Liaoning Science and Technology Press, 2021. | |
| [4] | TIAN J, ZHANG D, YAO X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study[J]. Ann Rheum Dis, 2023, 82(3):351-356. |
| [5] | LI M, WANG Y, ZHAO J, et al. Chinese SLE Treatment and Research Group (CSTAR) Registry 2009-2019: Major Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus[J]. Rheumatol Immunol Res, 2021, 2(1):43-47. |
| [6] | TEKTONIDOU M G, WANG Z, DASGUPTA A, et al. Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011[J]. Arthritis Care Res (Hoboken), 2015, 67(8):1078-1085. |
| [7] | FENG X, ZOU Y, PAN W, et al. Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China[J]. J Rheumatol, 2011, 38(7):1289-1295. |
| [8] | FENG X, PAN W, LIU L, et al. Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort[J]. PLoS One, 2016, 11(12):e0168619. |
| [9] | JIN Z, WANG F, PAN W, et al. Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus[J]. Rheumatology (Oxford), 2021, 60(4):1774-1783. |
| [10] | FANOURIAKIS A, KOSTOPOULOU M, ALUNNO A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6):736-745. |
| [11] | LU W, TIAN F, MA J, et al. Diagnostic accuracy of the European League against rheumatism/American College of Rheumatology-2019 versus the Systemic Lupus International Collaborating Clinics-2012 versus the ACR-1997 classification criteria in adult systemic lupus erythematosus: A systematic review and meta-analysis[J]. Front Immunol, 2022, 13:1023451. |
| [12] | ADAMICHOU C, GENITSARIDI I, NIKOLOPOULOS D, et al. Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus[J]. Ann Rheum Dis, 2021, 80(6):758-766. |
| [13] | GLADMAN D, GINZLER E, GOLDSMITH C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus[J]. Arthritis Rheum, 1996, 39(3):363-369. |
| [14] | YEE C S, SU L, TOESCU V, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years[J]. Rheumatology (Oxford), 2015, 54(5):836-843. |
| [15] | PETRI M, PURVEY S, FANG H, et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort[J]. Arthritis Rheum, 2012, 64(12):4021-4028. |
| [16] | LOPEZ R, DAVIDSON J E, BEEBY M D, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort[J]. Rheumatology (Oxford), 2012, 51(3):491-498. |
| [17] | BECKER-MEROK A, NOSSENT H C. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality[J]. J Rheumatol, 2006, 33(8):1570-1577. |
| [18] | DING H, SHEN Y, HONG S M, et al. Biomarkers for systemic lupus erythematosus - a focus on organ damage[J]. Expert Rev Clin Immunol, 2024, 20(1):39-58. |
| [19] | 中华医学会风湿病学分会,国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3):172-185. |
| Chinese Rheumatology Association, National Clinical Research Center for Dermatologic and Immunologic Diseases, Chinese Systemic Lupus Erythematosus Treatment and Research Group. 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus[J]. Chin J Intern Med, 2020, 59(3):172-185. | |
| [20] | YANG S C, LAI Y Y, HUANG M C, et al. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort[J]. Lupus, 2018, 27(11):1819-1827. |
| [21] | VAN VOLLENHOVEN R F, BERTSIAS G, DORIA A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force[J]. Lupus Sci Med, 2021, 8(1):e000538. |
| [22] | VAN VOLLENHOVEN R, VOSKUYL A, BERTSIAS G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)[J]. Ann Rheum Dis, 2017, 76(3):554-561. |
| [23] | FLORIS A, PIGA M, PERRA D, et al. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage[J]. Arthritis Care Res (Hoboken), 2020, 72(12):1794-1799. |
| [24] | PETRI M, MAGDER L S. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort[J]. Arthritis Rheumatol, 2018, 70(11):1790-1795. |
| [25] | VAN VOLLENHOVEN R F, STOHL W, FURIE R A, et al. Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study[J]. Lupus Sci Med, 2018, 5(1):e000288. |
| [26] | FANOURIAKIS A, KOSTOPOULOU M, ANDERSEN J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update[J]. Ann Rheum Dis, 2024, 83(1):15-29. |
| [27] | ROLAIN J M, COLSON P, RAOULT D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century[J]. Int J Antimicrob Agents, 2007, 30(4):297-308. |
| [28] | MOK C C, YING K Y, YIM C W, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up[J]. Ann Rheum Dis, 2016, 75(1):30-36. |
| [29] | GINZLER E M, DOOLEY M A, ARANOW C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis[J]. N Engl J Med, 2005, 353(21):2219-2228. |
| [30] | DOOLEY M A, JAYNE D, GINZLER E M, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis[J]. N Engl J Med, 2011, 365(20):1886-1895. |
| [31] | HUSSENBOCUS Y A A M, JIN Z, PAN W, et al. Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus[J]. Clin Rheumatol, 2022, 41(7):2043-2052. |
| [32] | FEI Y, SHI X, GAN F, et al. Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years[J]. Clin Rheumatol, 2014, 33(1):57-63. |
| [33] | ILLESCAS-MONTES R, CORONA-CASTRO C C, MELGUIZO-RODRíGUEZ L, et al. Infectious processes and systemic lupus erythematosus[J]. Immunology, 2019, 158(3):153-160. |
| [34] | NAVARRA S V, GUZMáN R M, GALLACHER A E, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011, 377(9767):721-731. |
| [35] | FURIE R, ROVIN B H, HOUSSIAU F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis[J]. N Engl J Med, 2020, 383(12):1117-1128. |
| [36] | ROVIN B H, FURIE R, TENG Y K O, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis[J]. Kidney Int, 2022, 101(2):403-413. |
| [37] | Kidney Disease: Improving Global Outcomes KDIGO Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS[J]. Kidney Int, 2024, 105(1S):S1-S69. |
| [38] | CHEN R, FU R, LIN Z, et al. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study[J]. Lupus, 2023, 32(1):94-100. |
| [39] | ROVIN B H, FURIE R, LATINIS K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study[J]. Arthritis Rheum, 2012, 64(4):1215-1226. |
| [40] | MOUGIAKAKOS D, KR?NKE G, V?LKL S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus[J]. N Engl J Med, 2021, 385(6):567-569. |
| [41] | CARNEY E F. Treatment of SLE with anti-CD19 CAR-T cells[J]. Nat Rev Nephrol, 2022, 18(12):743. |
| [42] | FURIE R, KHAMASHTA M, MERRILL J T, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus[J]. Arthritis Rheumatol, 2017, 69(2):376-386. |
| [43] | FURIE R A, MORAND E F, BRUCE I N, ET AL. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial[J]. Lancet Rheumatol, 2019, 1(4):e208-e219. |
| [44] | HE J, ZHANG X, WEI Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus[J]. Nat Med, 2016, 22(9):991-993. |
| [45] | HE J, ZHANG R, SHAO M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(1):141-149. |
| [46] | 中华医学会风湿病学分会, 中国医院协会临床新技术应用专业委员会. 异体间充质干细胞治疗系统性红斑狼疮专家共识[J]. 中华风湿病学杂志, 2022, 26(1):1-8. |
| Rheumatology and Immunology branch of the Chinese Medical Association, New Clinical Technologies Application Professional Committee of China Hospital Association. Expert consensus on allogeneic mesenchymal stem cells in the treatment of systemic lupus erythematosus[J]. Chin J Rheumatol, 2022, 26(1):1-8. | |
| [47] | WANG D, LI J, ZHANG Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study[J]. Arthritis Res Ther, 2014, 16(2):R79. |
| [48] | YUAN X, QIN X, WANG D, et al. Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients[J]. Nat Commun, 2019, 10(1):2498. |
/
| 〈 |
|
〉 |
